Download presentation
Presentation is loading. Please wait.
1
PCSK9 Inhibitors and Cardiovascular Outcomes
2
PCSK9 Inhibitors
3
CV Outcomes Clinical Trial Data For PCSK9 Inhibitors
4
ODYSSEY OUTCOMES Primary Efficacy Endpoint
5
ODYSSEY OUTCOMES Efficacy Subgroup With Baseline LDL-C 100 mg/dL (Median Baseline LDL-C 118 mg/dL)
6
FOURIER Primary Efficacy Endpoint
7
2013 ACC/AHA Guidelines to Manage Dyslipidemia
8
2017 Updated ACC Consensus Document on Role of Nonstatin Therapies for LDL-C Lowering
9
Clinical Implications of PCSK9 Inhibitor Outcome Trials
10
Safety of PCSK9 Inhibitors
11
FOURIER and ODYSSEY OUTCOMES
12
Overall Results For PCSK9 Inhibitor Outcome Trials
13
ODYSSEY OUTCOMES vs FOURIER Patient Histories
14
ODYSSEY OUTCOMES vs FOURIER LLTs and Lipids
15
PCSK9 CVOTs Key Scientific Points
16
ODYSSEY OUTCOMES Secondary Efficacy Endpoints Hierarchical Testing
17
A Target Range for LDL-C
18
FOURIER Lower CV Event Rates With Lower LDL-C Levels, as Low as 20 mg/dL (~0.5 mmol/L)
19
PCSK9 Inhibitors in Clinical Care
20
Comparison of Lipid Guidelines by Society
21
Populations to Consider a PCSK9 Inhibitor
22
Personalizing Treatment
23
PRIMO Study Incidence of Muscle AEs
24
2017 NLA Recommendations on the Use of PCSK9 Inhibitors
25
PCSK9 Inhibitors in Clinical Care
26
Patient Case
27
Patient Case Treatment Approach
28
Statin Intolerance
29
PCSK9 inhibitors in Patients with PAD
30
Abbreviations
31
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.